From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead?

Biochemical Pharmacology

Volumn 79, Issue 4, 2010, Pages 525-534

  D'Acquisto, Fulvio ^a   Maione, Francesco ^a   Pederzoli Ribeil, Magali ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antinflammatory drugs; Autoimmune diseases; Interleukin 15; Interleukin 17; Interleukin 18; Interleukin 21; Interleukin 22; Interleukin 27; Interleukin 33; Resolution of inflammation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 33; PROSTAGLANDIN; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 17A; RECOMBINANT INTERLEUKIN 27; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; BIOLOGICAL ACTIVITY; CYTOKINE RELEASE; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING;

EID: 71349086708     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.09.015     Document Type: Note

References (130)

1. Medzhitov R. Origin and physiological roles of inflammation. Nature 454 (2008) 428-435
2. Serhan C.N., Brain S.D., Buckley C.D., Gilroy D.W., Haslett C., O'Neill L.A., et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 21 (2007) 325-332
3. Serhan C.N., Chiang N., and Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8 (2008) 349-361
4. Atassi M.Z., and Casali P. Molecular mechanisms of autoimmunity. Autoimmunity 41 (2008) 123-132
5. Kanegane H., and Tosato G. Activation of naive and memory T cells by interleukin-15. Blood 88 (1996) 230-235
6. Rochman Y., Spolski R., and Leonard W.J. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9 (2009) 480-490
7. Orinska Z., Maurer M., Mirghomizadeh F., Bulanova E., Metz M., Nashkevich N., et al. IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. Nat Med 13 (2007) 927-934
8. Tagaya Y., Bamford R.N., DeFilippis A.P., and Waldmann T.A. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 4 (1996) 329-336
9. Tagaya Y., Kurys G., Thies T.A., Losi J.M., Azimi N., Hanover J.A., et al. Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. Proc Natl Acad Sci USA 94 (1997) 14444-14449
10. He Y.W., and Malek T.R. The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. Crit Rev Immunol 18 (1998) 503-524
11. Onu A., Pohl T., Krause H., and Bulfone-Paus S. Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms. J Immunol 158 (1997) 255-262
12. Sato N., Patel H.J., Waldmann T.A., and Tagaya Y. The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci USA 104 (2007) 588-593
13. Suzuki H., Duncan G.S., Takimoto H., and Mak T.W. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain. J Exp Med 185 (1997) 499-505
14. Schluns K.S., Nowak E.C., Cabrera-Hernandez A., Puddington L., Lefrancois L., and Aguila H.L. Distinct cell types control lymphoid subset development by means of IL-15 and IL-15 receptor alpha expression. Proc Natl Acad Sci USA 101 (2004) 5616-5621
15. Wilkinson P.C., and Liew F.Y. Chemoattraction of human blood T lymphocytes by interleukin-15. J Exp Med 181 (1995) 1255-1259
16. Badolato R., Ponzi A.N., Millesimo M., Notarangelo L.D., and Musso T. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood 90 (1997) 2804-2809
17. Fehniger T.A., and Caligiuri M.A. Interleukin 15: biology and relevance to human disease. Blood 97 (2001) 14-32
18. McInnes I.B., and Liew F.Y. Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 19 (1998) 75-79
19. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8 (2008) 337-348
20. Oukka M. Th17 cells in immunity and autoimmunity. Ann Rheum Dis 67 Suppl. 3 (2008) iii26-iii29
21. Kolls J.K., and Linden A. Interleukin-17 family members and inflammation. Immunity 21 (2004) 467-476
22. Gaffen S.L. An overview of IL-17 function and signaling. Cytokine 43 (2008) 402-407
23. Rong Z., Wang A., Li Z., Ren Y., Cheng L., Li Y., et al. IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling. Cell Res 19 (2009) 208-215
24. Iwakura Y., Nakae S., Saijo S., and Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 226 (2008) 57-79
25. Schwarzenberger P., La Russa V., Miller A., Ye P., Huang W., Zieske A., et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol 161 (1998) 6383-6389
26. Maione F., Paschalidis N., Mascolo N., Dufton N., Perretti M., and D'Acquisto F. Interleukin 17 sustains rather than induces inflammation. Biochem Pharmacol 77 (2009) 878-887
27. Awasthi A., and Kuchroo V.K. Th17 cells: from precursors to players in inflammation and infection. Int Immunol 21 (2009) 489-498
28. Fouser L.A., Wright J.F., Dunussi-Joannopoulos K., and Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 226 (2008) 87-102
29. Steinman L. A rush to judgment on Th17. J Exp Med 205 (2008) 1517-1522
30. Fantuzzi G., and Dinarello C.A. Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). J Clin Immunol 19 (1999) 1-11
31. Novick D., and Rubinstein M. The tale of soluble receptors and binding proteins: from bench to bedside. Cytokine Growth Factor Rev 18 (2007) 525-533
32. Novick D., Kim S.H., Fantuzzi G., Reznikov L.L., Dinarello C.A., and Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10 (1999) 127-136
33. Fantuzzi G., Banda N.K., Guthridge C., Vondracek A., Kim S.H., Siegmund B., et al. Generation and characterization of mice transgenic for human IL-18-binding protein isoform a. J Leukoc Biol 74 (2003) 889-896
34. Dunne A., and O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003 (2003) re3
35. O'Neill L.A., and Greene C. Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol 63 (1998) 650-657
36. Gutcher I., Urich E., Wolter K., Prinz M., and Becher B. Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation. Nat Immunol 7 (2006) 946-953
37. Wyburn K., Wu H., Chen G., Yin J., Eris J., and Chadban S. Interleukin-18 affects local cytokine expression but does not impact on the development of kidney allograft rejection. Am J Transplant 6 (2006) 2612-2621
38. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol 12 (2000) 59-63
39. Okamura H., Tsutsui H., Kashiwamura S., Yoshimoto T., and Nakanishi K. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 70 (1998) 281-312
40. Sugawara I. Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens. Microbes Infect 2 (2000) 1257-1263
41. Gherardi M.M., Ramirez J.C., and Esteban M. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol 84 (2003) 1961-1972
42. Hoshino T., Wiltrout R.H., and Young H.A. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 162 (1999) 5070-5077
43. Xu D., Trajkovic V., Hunter D., Leung B.P., Schulz K., Gracie J.A., et al. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol 30 (2000) 3147-3156
44. Wild J.S., Sigounas A., Sur N., Siddiqui M.S., Alam R., Kurimoto M., et al. IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol 164 (2000) 2701-2710
45. Hoshino T., Yagita H., Ortaldo J.R., Wiltrout R.H., and Young H.A. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol 30 (2000) 1998-2006
46. Hoshino T., Kawase Y., Okamoto M., Yokota K., Yoshino K., Yamamura K., et al. Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol 166 (2001) 7014-7018
47. Dinarello C.A. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 27 (2007) 98-114
48. Smeets R.L., van de Loo F.A., Arntz O.J., Bennink M.B., Joosten L.A., and van den Berg W.B. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther 10 (2003) 1004-1011
49. Banda N.K., Vondracek A., Kraus D., Dinarello C.A., Kim S.H., Bendele A., et al. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J Immunol 170 (2003) 2100-2105
50. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57-63
51. Leonard W.J., and Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 5 (2005) 688-698
52. Mehta D.S., Wurster A.L., and Grusby M.J. Biology of IL-21 and the IL-21 receptor. Immunol Rev 202 (2004) 84-95
53. Collins M., Whitters M.J., and Young D.A. IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity. Immunol Res 28 (2003) 131-140
54. Pesce J., Kaviratne M., Ramalingam T.R., Thompson R.W., Urban Jr. J.F., Cheever A.W., et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 116 (2006) 2044-2055
55. Fina D., Sarra M., Fantini M.C., Rizzo A., Caruso R., Caprioli F., et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 134 (2008) 1038-1048
56. Wei L., Laurence A., Elias K.M., and O'Shea J.J. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 282 (2007) 34605-34610
57. Ozaki K., Spolski R., Ettinger R., Kim H.P., Wang G., Qi C.F., et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 173 (2004) 5361-5371
58. Konforte D., Simard N., and Paige C.J. IL-21: an executor of B cell fate. J Immunol 182 (2009) 1781-1787
59. Ettinger R., Kuchen S., and Lipsky P.E. The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 223 (2008) 60-86
60. Brandt K., Bulfone-Paus S., Foster D.C., and Ruckert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102 (2003) 4090-4098
61. Fantini M.C., Rizzo A., Fina D., Caruso R., Becker C., Neurath M.F., et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 37 (2007) 3155-3163
62. Zeng R., Spolski R., Finkelstein S.E., Oh S., Kovanen P.E., Hinrichs C.S., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 201 (2005) 139-148
63. White L., Krishnan S., Strbo N., Liu H., Kolber M.A., Lichtenheld M.G., et al. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV). Blood 109 (2007) 3873-3880
64. Sivori S., Cantoni C., Parolini S., Marcenaro E., Conte R., Moretta L., et al. IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol 33 (2003) 3439-3447
65. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B., et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16 (2002) 559-569
66. Herber D., Brown T.P., Liang S., Young D.A., Collins M., and Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 178 (2007) 3822-3830
67. Jang E., Cho S.H., Park H., Paik D.J., Kim J.M., and Youn J. A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+CD25- T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice. J Immunol 182 (2009) 4649-4656
68. Young D.A., Hegen M., Ma H.L., Whitters M.J., Albert L.M., Lowe L., et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 56 (2007) 1152-1163
69. Vollmer T.L., Liu R., Price M., Rhodes S., La Cava A., and Shi F.D. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 174 (2005) 2696-2701
70. Nagem R.A., Ferreira Junior J.R., Dumoutier L., Renauld J.C., and Polikarpov I. Interleukin-22 and its crystal structure. Vitam Horm 74 (2006) 77-103
71. Wolk K., and Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 17 (2006) 367-380
72. Zenewicz L.A., and Flavell R.A. IL-22 and inflammation: leukin' through a glass onion. Eur J Immunol 38 (2008) 3265-3268
73. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., and Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22 (2004) 929-979
74. Aujla S.J., and Kolls J.K. IL-22: a critical mediator in mucosal host defense. J Mol Med 87 (2009) 451-454
75. Takatori H., Kanno Y., Watford W.T., Tato C.M., Weiss G., Ivanov I.I., et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 206 (2009) 35-41
76. Veldhoen M., Hirota K., Westendorf A.M., Buer J., Dumoutier L., Renauld J.C., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453 (2008) 106-109
77. Radaeva S., Sun R., Pan H.N., Hong F., and Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39 (2004) 1332-1342
78. Ma H.L., Liang S., Li J., Napierata L., Brown T., Benoit S., et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 118 (2008) 597-607
79. Aggarwal S., Xie M.H., Maruoka M., Foster J., and Gurney A.L. Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res 21 (2001) 1047-1053
80. Nagalakshmi M.L., Rascle A., Zurawski S., Menon S., and de Waal Malefyt R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 4 (2004) 679-691
81. Pan H., Hong F., Radaeva S., and Gao B. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 1 (2004) 43-49
82. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Karow M., and Flavell R.A. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 27 (2007) 647-659
83. Harper E.G., Guo C., Rizzo H., Lillis J.V., Kurtz S.E., Skorcheva I., et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol (2009)
84. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203 (2006) 2271-2279
85. Wolk K., Witte E., Wallace E., Docke W.D., Kunz S., Asadullah K., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36 (2006) 1309-1323
86. Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 118 (2008) 534-544
87. Lankford C.S., and Frucht D.M. A unique role for IL-23 in promoting cellular immunity. J Leukoc Biol 73 (2003) 49-56
88. Frucht D.M. IL-23: a cytokine that acts on memory T cells. Sci STKE 2002 (2002) PE1
89. Watford W.T., Hissong B.D., Bream J.H., Kanno Y., Muul L., and O'Shea J.J. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 202 (2004) 139-156
90. Tato C.M., and Cua D.J. Reconciling id, ego, and superego within interleukin-23. Immunol Rev 226 (2008) 103-111
91. Becher B., Durell B.G., and Noelle R.J. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 112 (2003) 1186-1191
92. Ciccia F., Bombardieri M., Principato A., Giardina A., Tripodo C., Porcasi R., et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 60 (2009) 955-965
93. Boniface K., Blom B., Liu Y.J., and de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev 226 (2008) 132-146
94. Furuzawa-Carballeda J., Vargas-Rojas M.I., and Cabral A.R. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 6 (2007) 169-175
95. Leithauser F., Meinhardt-Krajina T., Fink K., Wotschke B., Moller P., and Reimann J. Foxp3-expressing CD103+ regulatory T cells accumulate in dendritic cell aggregates of the colonic mucosa in murine transfer colitis. Am J Pathol 168 (2006) 1898-1909
96. Izcue A., Hue S., Buonocore S., Arancibia-Carcamo C.V., Ahern P.P., Iwakura Y., et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28 (2008) 559-570
97. Caruso R., Pallone F., and Monteleone G. Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol 13 (2007) 5547-5551
98. Caruso R., Sarra M., Stolfi C., Rizzo A., Fina D., Fantini M.C., et al. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology 136 (2009) 2270-2279
99. Amre D.K., Mack D., Israel D., Morgan K., Lambrette P., Law L., et al. Association between genetic variants in the IL-23R gene and early-onset Crohn's disease: results from a case-control and family-based study among Canadian children. Am J Gastroenterol 103 (2008) 615-620
100. Dubinsky M.C., Wang D., Picornell Y., Wrobel I., Katzir L., Quiros A., et al. IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm Bowel Dis 13 (2007) 511-515
101. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5 (2005) 521-531
102. Batten M., and Ghilardi N. The biology and therapeutic potential of interleukin 27. J Mol Med 85 (2007) 661-672
103. Yoshida H., and Yoshiyuki M. Regulation of immune responses by interleukin-27. Immunol Rev 226 (2008) 234-247
104. Kastelein R.A., Hunter C.A., and Cua D.J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 25 (2007) 221-242
105. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16 (2002) 779-790
106. Villarino A.V., Larkin III J., Saris C.J., Caton A.J., Lucas S., Wong T., et al. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J Immunol 174 (2005) 7684-7691
107. Yoshida H., Hamano S., Senaldi G., Covey T., Faggioni R., Mu S., et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 15 (2001) 569-578
108. Hamano S., Himeno K., Miyazaki Y., Ishii K., Yamanaka A., Takeda A., et al. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19 (2003) 657-667
109. Villarino A., Hibbert L., Lieberman L., Wilson E., Mak T., Yoshida H., et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19 (2003) 645-655
110. Larousserie F., Pflanz S., Coulomb-L'Hermine A., Brousse N., Kastelein R., and Devergne O. Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol 202 (2004) 164-171
111. Artis D., Villarino A., Silverman M., He W., Thornton E.M., Mu S., et al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol 173 (2004) 5626-5634
112. Wirtz S., Tubbe I., Galle P.R., Schild H.J., Birkenbach M., Blumberg R.S., et al. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J Exp Med 203 (2006) 1875-1881
113. Dinarello C.A. An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor. Immunity 23 (2005) 461-462
114. Arend W.P., Palmer G., and Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223 (2008) 20-38
115. Gadina M., and Jefferies C.A. IL-33: a sheep in wolf's clothing?. Sci STKE 2007 (2007) pe31
116. Carriere V., Roussel L., Ortega N., Lacorre D.A., Americh L., Aguilar L., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104 (2007) 282-287
117. Kakkar R., and Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7 (2008) 827-840
118. Komai-Koma M., Xu D., Li Y., McKenzie A.N., McInnes I.B., and Liew F.Y. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 37 (2007) 2779-2786
119. Iwahana H., Yanagisawa K., Ito-Kosaka A., Kuroiwa K., Tago K., Komatsu N., et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 264 (1999) 397-406
120. Tominaga S., Kuroiwa K., Tago K., Iwahana H., Yanagisawa K., and Komatsu N. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun 264 (1999) 14-18
121. Bruneau S., Le Berre L., Herve C., Valanciute A., Kamal M., Naulet J., et al. Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation. Am J Kidney Dis (2009)
122. Mueller T., Dieplinger B., Gegenhuber A., Poelz W., Pacher R., and Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 54 (2008) 752-756
123. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (2005) 479-490
124. Allakhverdi Z., Smith D.E., Comeau M.R., and Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 179 (2007) 2051-2054
125. Moulin D., Donze O., Talabot-Ayer D., Mezin F., Palmer G., and Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40 (2007) 216-225
126. Xu D., Jiang H.R., Kewin P., Li Y., Mu R., Fraser A.R., et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 105 (2008) 10913-10918
127. Leung B.P., Xu D., Culshaw S., McInnes I.B., and Liew F.Y. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 173 (2004) 145-150
128. Sweet M.J., Leung B.P., Kang D., Sogaard M., Schulz K., Trajkovic V., et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 166 (2001) 6633-6639
129. Kopp E., and Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265 (1994) 956-959
130. Claria J., and Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92 (1995) 9475-9479